STANDARD TREATMENT WITH BEVACIZUMAB AS TARGETED THERAPY IN CERVICAL CANCER

被引：0

作者：

Enriquez-Aceves, Isabel ^{[1
]}

Galicia-Carmona, Tatiana ^{[2
,3
]}

Coronel-Martinez, Jaime A. ^{[2
,3
]}

Espinosa-Romero, Raquel ^{[3
]}

Calderillo-Ruiz, German ^{[3
]}

Cortes-Esteban, Patricia ^{[4
]}

Cetina-Perez, Lucely ^{[2
,3
]}

机构：

[1] Hosp Inst Seguridad & Serv Sociales Trabajadores, Dept Med Oncol, Leon, Gto, Mexico

[2] Inst Nacl Cancerol, Dept Clin Res, Mexico City, DF, Mexico

[3] Inst Nacl Cancerol, Dept Med Oncol, Mexico City, DF, Mexico

[4] Ctr Med Nacl 20 Noviembre, Dept Med Oncol, Mexico City, DF, Mexico

来源：

REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION | 2020年 / 72卷 / 04期

关键词：

Bevacizumab; Cervical; Cancer; Metastatic antiangiogenic; PHASE-II TRIAL; SQUAMOUS-CELL-CARCINOMA; COMBINATION THERAPY; 3RD-LINE TREATMENT; OPEN-LABEL; RECURRENT; PERSISTENT; CHEMOTHERAPY; CARBOPLATIN; PACLITAXEL;

D O I：

10.24875/RIC.20000061

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Metastatic, recurrent, or persistent disease in cervical cancer has a poor prognosis. Historically, this group of patients has had limited treatment options, even with the best cytotoxic treatments (platinum-based chemotherapy [CT] doublets). Therefore, investigating new medications that help improve the patient's quality of life and survival has been essential. Angiogenesis has been shown to play a critical role in tumor cell growth and survival. Bevacizumab is a recombinant humanized monoclonal G1 immunoglobulin targeted against vascular endothelial growth factor. The combination of CT and bevacizumab is associated with an increase in overall survival as well as in progression-free survival and response rates.

引用

页码：213 / 218

页数：6

共 50 条

[31] Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB-IIB cervical cancer
Maene, Charlotte
Salihi, Rawand Rokan
Van Nieuwenhuysen, Els
Han, Sileny N.
Concin, Nicole
Vergote, Ignace
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (06) : 824 - 828
[32] Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer
Crafton, Sarah M.
Salani, Ritu
CLINICAL THERAPEUTICS, 2016, 38 (03) : 449 - 458
[33] Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer
Eskander, Ramez N.
Tewari, Krishnansu S.
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2014, 25 (03) : 249 - 259
[34] Interstitial fluid pressure in cervical cancer - Guide to targeted therapy
Milosevic, M
Fyles, A
Hill, R
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (05): : 516 - 521
[35] Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer
Patricia J Eifel
Nature Clinical Practice Oncology, 2006, 3 : 248 - 255
[36] What Is the Standard Therapy for Bulky Stage IB Cervical Cancer?
Monk, Bradley J.
Koh, Wui-Jin
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (03) : 480 - 480
[37] Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer
Eifel, PJ
NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (05): : 248 - 255
[38] Imaging on Lung Cancer and Treatment with Targeted Therapy
Shroff, Girish S.
Benveniste, Marcelo F.
de Groot, Patricia M.
Carter, Brett W.
Wu, Carol C.
Viswanathan, Chitra
Truong, Mylene T.
SEMINARS IN ULTRASOUND CT AND MRI, 2018, 39 (03) : 308 - 313
[39] Advances in Treatment of Lung Cancer With Targeted Therapy
Cagle, Philip T.
Chirieac, Lucian R.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (05) : 504 - 509
[40] Molecular targeted therapy for the treatment of gastric cancer
Wenting Xu
Zhen Yang
Nonghua Lu
Journal of Experimental & Clinical Cancer Research, 35

← 1 2 3 4 5 →